All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fdom.12197

Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research